References
- Provencio M, Millán I, España P, et al Analysis of competing risk of causes of death and their variation over different time periods in Hodgkin disease. Clinical Cancer Res 2008;14:5300–5305.
- Bodis S, Henry-Amar M, Bosq J, et al Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 1993;11:225–232.
- Weiss LM, Warnke RA, Hansmann ML, et al Pathology of Hodgkin lymphoma. In: Hoppe RT, Mauch PM, Armitage JO, Diehl V, Weiss LM, editors. Hodgkin Lymphoma. 2nd ed. Alphen aan den Rijn, The Netherlands: Wolters Kluwer; 2007. pp. 43–71.
- Van Wasielewsi R, Mengel M, Fischer R, et al Classical Hodgkin's disease: clinical impact of immunophenotype. Am J Pathol 1997;151:1123–1130.
- Carbone PP, Kaplan HS, Musshoff K, et al Report of the Committee on Hodgkin's disease Staging Classification. Cancer Res 1971;31:1860–1861.
- Lister TA, Crowther D, Sutcliffe SB, et al Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
- De Vita VT, Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc Am Assoc Cancer Res 1967;8:13.
- Bonadonna G, Zucali R, Monfardini S, et al Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252–259.
- Kaplan HS, Rosenberg SA. Extended field radical radiotherapy in advanced Hodgkin's disease. Cancer Res 1966;26:1268–1276.
- Aragón de la Cruz G, Cardenes H, Otero J, et al Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin's disease. A rule index based on 341 laparotomized patients. Cancer 1989;63:1799–1803.
- Sieniawski M, Franklin J, Nogova L, et al Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favourable Hodgkin's lymphoma. J Clin Oncol 2007;25:2000–2005.
- Facon T. High incidence of late relapses in advanced Hodgkin's disease among patients treated by chemotherapy alone. Presented at 2nd International Symposium on Hodgkin's disease, 3–5 October 1991, Cologne, Germany.
- Provencio M, España P, Salas C, Sánchez A, Bonilla F. Hodgkin's disease: unsuspected minimal activity in patients that die from causes other than tumoral progression. Leuk Lymphoma 2001;42:661–664.
- Liedtke M, Hamlin PA, Moskowi CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006;17:909–913.
- Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:123–125.
- Josting A, Franklin J, May M, et al A new prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). J Clin Oncol 2002;20:221–230.
- Hutchings M, Specht L. PET/CT in the management of haematological malignancies. Eur J Haematol 2008;80:369–380.
- Hutchings M, Loft A, Hansen M, et al FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin's lymphoma. Blood 2006;107:52–59.